ReadyCell actively interacts with the Drug Discovery community, introducing cell-based in vitro systems and easing novel compounds’ preclinical development.
Strategies for successful Drug Discovery and Development at the BTS Discovery Toxicology 2023
Lourdes Gombau, head of the R&D Department, and Maria Riba, Business Development Manager, presented in the UK the last scientific article of the company, shedding light on the topic of compound intestinal toxicity.
